Corabotase

Phase 2

Ipsen

Corabotase is one of 12 therapeutic programs targeting Cervical Dystonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cervical DystoniaRecruiting

Moderate to Severe Upper Facial LinesActive, not recruiting

SpasticityRecruiting

Cervical DystoniaPhase 2

Recruiting

Moderate to Severe Upper Facial LinesPreclinical

Active, not recruiting

SpasticityPreclinical

Recruiting

Competition

Competitive Landscape

7 competitors in Cervical Dystonia

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Phase 2

1 2

IPN10200

Ipsen

Phase 2

1 3

Corabotase

Ipsen

Phase 2

1 4

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

1 5

Zinc Citrate

UUniversity of Florida

Phase 2

1 6

Botulinum Toxin

MMeshalkin Research Institute of Pathology of Circulation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Moderate to Severe Glabellar Lines

NCT07427797

PreclinicalActive, not recruiting

Moderate to Severe Upper Facial Lines

NCT04821089

Q4 2027

Phase 2Active, not recruiting

Episodic Migraine

NCT06625060

Phase 2Recruiting

Cervical Dystonia

NCT06937931

Q2 2028

Phase 3Recruiting

Moderate to Severe Glabellar Lines

NCT07779252

Q4 2028

Phase 3Recruiting

Moderate to Severe Glabellar Lines

NCT07435428

Clinical

Trials by Indication[1]

Moderate to Severe Glabellar Lines3 trials

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of IPN10200 in the Improvement of the Appearance of Moderate To Severe Glabellar Lines in Adult Chinese Participants

Recruiting· Ipsen logo

Ipsen·Phase 3·NCT07779252·160 enrolled

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants

Active, not recruiting· Ipsen logo

Ipsen·Phase 3·NCT07427797·309 enrolled

A Phase III, Multicentre, Double-blind, Randomised, Placebo-controlled and Open-label Study to Evaluate the Efficacy and Safety of a Single Dose of IPN10200 in the Improvement of Moderate to Severe Glabellar Lines in Adult Participants, and to Evaluate the Long-term Efficacy and Safety of Repeat Doses of IPN10200 in the Same Indication

Recruiting· Ipsen logo

Ipsen·Phase 3·NCT07435428·1,300 enrolled

Moderate to Severe Upper Facial Lines1 trial

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Active, not recruiting· Ipsen logo

Ipsen·Preclinical·NCT04821089·727 enrolled

Episodic Migraine1 trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

Active, not recruiting· Ipsen logo

Ipsen·Phase 2·NCT06625060·670 enrolled

Cervical Dystonia1 trial

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

Recruiting· Ipsen logo

Ipsen·Phase 2·NCT06937931·132 enrolled

Spasticity1 trial

An Integrated Phase I/II, Multicentre, Double-blind, Randomised, Dysport and Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in the Treatment of Adult Upper Limb Spasticity.

Recruiting· Ipsen logo

Ipsen·Preclinical·NCT04752774·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Corabotase. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Corabotase. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ipsen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Ipsen

Corabotase

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q2 2028

Q4 2028

Trials by Indication[1]

Moderate to Severe Glabellar Lines3 trials

Moderate to Severe Upper Facial Lines1 trial

Episodic Migraine1 trial

Cervical Dystonia1 trial

Spasticity1 trial

References

Drug Info

Quick Facts

Related News